Plaisance Capital
VC Fund
Denver, United States
Plaisance Capital is a VC fund in Denver focused on Medical and Health Care. Plaisance Capital is committed to a Contrarian Value investment philosophy.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Plaisance Capital invests in
Stages Plaisance Capital invests in
Countries Plaisance Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Frederick Jiang
|
|||
4 more contacts available
Investment Focus
Industry
- Medical 1 (33%)
- Health Care 1 (33%)
- Medical Device 1 (33%)
- Personal Health 1 (33%)
- Home Health Care 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
- Series B 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Frederick Jiang
Managing Partner
|
Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
ALLYRNA Pharmaceuticals
|
ALLYRNA, an innovative small molecule drug developer focused on first-in-class drug development, has established a unique platform for radiotherapy and immunotherapy sensitizers. | $10M / Seed / Aug 27, 2025 | |
Corsair Pharma
|
Corsair Pharma is developing transformative solutions to the therapeutic profile of medications and provide superior treatment for patients. | $23M / Series B / Sep 20, 2023 | |
Smartlens
|
Smartlens is a clinical-stage Med Tech company with a portfolio of technologies to treat and diagnose Glaucoma - a chronic eye disease and the leading cause of irreversible blindness. The Company is running clinical trials with its novel eye pressure (IOP) monitoring contact lens (miLens) that will help improve clinical outcomes in Glaucoma. Thedisease affects hundreds of millions around the globe; even in developed countries more than 50% of the patients are currently undiagnosed, and more than 38% are going blind despite being treated. The need for monitoring eye pressure outside the clinic has been defined as an urgent need by scientific, medical, and industry leaders in ophthalmology that will help improve clinical outcomes. Smartlens’ flagship product miLens is a non-invasive and convenient way of monitoring eye pressure for anyone anywhere at any time. It will help improve early diagnosis, enable personalized treatments, and disease monitoring thus reducing the prevalence of blindness, treatment costs, and its huge burden on lives and economies. miLens is utilizing a novel, electronics-free sensor technology that is fully owned by Smartlens, Inc. and protected by its portfolio of issued and pending patents covering more than 40 countries. The Company's novel technology is also being studied at Stanford University Labs for monitoring (ICP) which is associated with certain neurological disorders, and cancers. Smartlens also owns a non-invasive drug delivery technology that monitors the IOP and releases the right medication at the right time which will help improve efficacy, patient compliance and reduce the side effects. Smartlens is the Winner of the 2021 "Outstanding Innovation in Medical Technology and Life Sciences" of High-Tech Awards by Octane. The Company has been invited to various national and international conferences, published its studies, listed among the Top 10 MedTech Startups, and featured in ABC7, Fortune, BBC, and Nature Medicine. | $6.1M / Series A / Jul 11, 2023 |
Co-Investors
Plaisance Capital Management
2 deals together
3E Bioventures
1 deal together
Ambit Health Ventures
1 deal together
Gaorong Capital
1 deal together
Boutique Venture Partners
1 deal together
Graphene Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Plaisance Capital invest in?
Plaisance Capital invests primarily in Medical, Health Care and Medical Device startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Plaisance Capital?
Public channels for Plaisance Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Plaisance Capital?
The team at Plaisance Capital includes Frederick Jiang (Managing Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
